Core Viewpoint - The company announced that its stock price has experienced an abnormal fluctuation, with a cumulative decline of over 20% in closing prices over three consecutive trading days in 2026, but no undisclosed significant information affecting the stock price has been found [1] Group 1 - The company confirmed that there is no need to correct or supplement previously disclosed information, and the operating conditions and environment remain unchanged [1] - The controlling shareholder and actual controller have no undisclosed significant matters [1] - During the period of abnormal fluctuation, there were no transactions involving the company's stock [1] Group 2 - The company is currently conducting financial accounting for the year 2025 [1] - The commercialization of brain-machine interface and brain-like intelligence business is still in its early stages and has not yet generated revenue [1]

Core Viewpoint - The market is expected to enter a short-term consolidation phase, with structural differentiation emerging in investment themes and sectors [4][11]. Group 1: Market Overview - The market continued to rise last week, but investor sentiment declined in the latter half due to increased financing margin ratios and pullbacks in themes like commercial aerospace [4][11]. - The current risk premium in the A-share market has dropped to the lower end of the range, indicating a need for fundamental support or strong incremental capital for further downward breakthroughs [4][11]. Group 2: Investment Strategy - The investment strategy should focus on potential expansion directions in thematic investments, such as domestic computing power, humanoid robots, brain-computer interfaces, and AI applications [4][11]. - For cyclical investments, attention should be given to sectors with dual supply and demand improvements, including the new energy chain, storage, certain chemicals, consumer goods, and engineering machinery [4][11]. Group 3: Fund Flows - The top three industries for net capital inflow are construction materials (+6.26 billion), electric power equipment (+11.45 billion), and banking (+6.12 billion) [3][10].

Core Viewpoint - The establishment of a total of 17 strategic partnerships between Hainan Holdings and major banks marks a significant step in the financial support for the Hainan Free Trade Port, enhancing credit capacity and optimizing financial resources for key projects and new industries [5][6]. Financial Institutions' Involvement - Hainan Holdings has achieved a financial credit limit exceeding 200 billion yuan, partnering with 17 banks, including major state-owned banks and joint-stock banks, to support various sectors such as infrastructure and new productivity [2][3]. - The total assets of the banking sector in Hainan Free Trade Port reached 1,959.8 billion yuan by October 2025, reflecting a 39.68% increase since the end of 2020, while the insurance sector's total assets grew by 47.99% to 70.5 billion yuan [3]. Strategic Cooperation Significance - The strategic cooperation with banks aims to enhance funding security, increase credit flexibility, and lower financing costs, thereby supporting Hainan Holdings' core and emerging business sectors [5][6]. - Hainan Holdings is recognized as a key strategic partner for several banks, indicating its significant role in the regional economic landscape [5]. Diverse Financial Support System - The 17 banks provide a diversified financial support system, leveraging their unique strengths to meet the specific needs of Hainan's economic development [8][9]. - Major banks like the Industrial and Commercial Bank of China and China Construction Bank focus on project financing and supply chain finance, while others like the Agricultural Development Bank emphasize policy-driven financial support [9][10]. Non-Banking Financial Institutions - Non-banking financial institutions, including insurance companies and venture capital funds, are also increasing their investments in Hainan, with notable entries from HSBC and Allianz [12][13]. - The Hainan Free Trade Port Construction Fund has doubled its registered capital to 20 billion yuan, reflecting a strong commitment to long-term development and support for enterprises [13][14]. Future Industry Focus - The Hainan Free Trade Port Construction Fund plans to focus on advanced sectors such as biomanufacturing and hydrogen energy, aiming to create a collaborative ecosystem for technology transfer and market expansion [14]. - The establishment of a gold storage facility in Hainan marks a significant development in the local financial infrastructure, facilitating efficient and secure operations for the gold industry [14].

国家统计局1月19日发布数据初步核算2025年中国国内生产总值（GDP）达到1401879亿元按不变价格计算比上年增长5.0%。 国家统计局1月19日发布数据 高质量发展取得新成效 经济社会发展主要目标任务圆满实现 初步核算 2025年中国国内生产总值（GDP）达到1401879亿元 按不变价格计算 比上年增长5.0% 面对国内外经济环境的复杂变化 国民经济运行顶压前行、向新向优 "十四五"胜利收官 "十四五"期间 中国经济总量连续跨越 110万亿元、120万亿元、130万亿元、140万亿元关口 本文来源：新华社 记者：王雨萧、张晓洁 海报制作：贾稀荃 如何评价2025年我国经济表现？国家统计局用"稳、进、新、韧"四字作答 2025年是"十四五"规划收官之年，也是中国式现代化进程中具有重要意义的一年。如何评价这一年我国经济表现？国家统计局局长康义 19日在国新办发布会上用"稳、进、新、韧"四个字作答。 首先是"稳"的格局得到巩固。康义说，2025年，"稳"是我国经济突出特点。面对外部环境急剧变化，国内困难挑战增多的复杂严峻形 势，我国实施更加积极有为的宏观政策，不仅有效化解外部环境变化的不利影响，更在风浪中稳 ...

格隆汇1月19日丨海利得(002206.SZ)在投资者互动平台表示，目前公司LCP相关产品尚未应用在脑机接 口业务。 ...

Core Viewpoint - The company, Zhijiang Biology, confirmed that it does not currently engage in brain-computer interface (BCI) related business activities [1] Group 1: Company Overview - Zhijiang Biology's main business focuses on molecular diagnostic reagents and equipment [1] - The applications of the company's products include medical clinical diagnosis, public health safety, entry-exit inspection and quarantine, and food safety [1] - The company has not expanded into the brain-computer interface sector [1]

Market Overview - On the 19th, the Shanghai Composite Index experienced fluctuations and rose, while the ChiNext Index saw a decline of over 1% at one point; more than 3,500 stocks in the A-share market were in the green [1] - By the close, the Shanghai Composite Index increased by 0.29% to 4,114 points, the Shenzhen Component Index slightly rose by 0.09%, and the ChiNext Index fell by 0.7%; the total trading volume in the Shanghai, Shenzhen, and North markets was approximately 2.73 trillion yuan [1] Sector Performance - Sectors such as semiconductors, banking, and insurance saw declines, while military industry, tourism, steel, coal, non-ferrous metals, and food and beverage sectors experienced gains [1] - Active themes included ultra-high voltage, military trade concepts, Hainan free trade, and wind power [1] Investment Sentiment - Huatai Securities noted that while the market continued to rise last week, investor sentiment declined due to events such as the increase in financing margin ratios and the pullback of themes like commercial aerospace; the current A-share risk premium has dropped to the lower end of the range [1] - Historically, further downward breakthroughs (indicating improved risk appetite) require fundamental support or strong incremental capital, both of which currently have low visibility; however, the current policy direction is positive, the inherent stability of the capital market has increased, and investor sentiment remains strong [1] Short-term Market Outlook - The market is expected to enter a short-term consolidation phase, with structural differentiation beginning to emerge; both thematic and cyclical investments have room for development [1] - For thematic investments, potential expansion directions include domestic computing power, humanoid robots, brain-computer interfaces, and AI applications; for cyclical investments, continued focus on the new energy chain with dual supply and demand improvements, storage, certain chemicals, consumer goods, and construction machinery is recommended [1]

Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.29% and the ChiNext Index falling by 0.7% [2] - Over 3,500 stocks in the market experienced gains, while the total trading volume in the Shanghai and Shenzhen markets was 2.71 trillion yuan, a decrease of 317.9 billion yuan from the previous trading day [2] Sector Performance - Leading sectors included electric grid equipment, robotics, tourism and hotels, and precious metals, while the CPO concept faced declines [2] - The average stock price of the entire A-share market continued to rise, reaching the high point of the previous week [5] Fund Flow and ETF Activity - There was a notable reduction in heavy selling pressure from large funds in several major ETFs, indicating a potential stabilization in the market [7] - The trading volume of the Huatai-PB CSI 300 ETF was 13.793 billion yuan, showing a significant decrease in selling activity compared to previous days [7] Market Sentiment and Stock Performance - The number of stocks hitting the daily limit down decreased to 30, down from 72 and 61 in the previous two trading days, indicating a potential recovery in market sentiment [15] - Stocks such as Jin Feng Technology and Yan Shan Technology saw significant trading activity, with Jin Feng Technology recovering to a closing gain of 2.44% [13][12] Institutional Insights - Citic Securities noted that the recent market cooling is a strategic move to manage the bull market's pace, suggesting that the overall market sentiment remains positive despite short-term adjustments [17] - Guosheng Securities indicated that the market's short-term adjustment may be nearing completion, with a likelihood of continued upward movement in the near future [18]

智通财经APP获悉，华福证券发布研报称，近期，超声脑机接口公司MergeLabs完成约2.5亿美元种子轮 融资，此次融资由OpenAI领投。不同于主流脑机接口技术，MergeLabs聚焦超声为核心的非侵入或极 低侵入式路线。MergeLabs的超声路线试图在非侵入式(安全但分辨率有限)与植入式(信号清晰但有外科 风险、伦理监管问题)之间寻找平衡，其超声的深部穿透能力与"软接口"设想具备独特潜力。但该技术 目前仍处于实验室研究阶段。 当前脑机接口主要分为非侵入式、植入式及低侵入式三类路径，MergeLabs的超声路线试图在非侵入式 (安全但分辨率有限)与植入式(信号清晰但有外科风险、伦理监管问题)之间寻找平衡，其超声的深部穿 透能力与"软接口"设想具备独特潜力。但该技术目前仍处于实验室研究阶段，面临分子信号稳定性、超 声空间分辨率与安全窗口、低信噪比下神经状态反推等多重未解决的难题，复杂性不亚于植入式系统。 "十五五"重点赛道，脑机接口市场规模有望快速增长 根据Precedence research，2024年全球脑机接口市场规模约为26.2亿美元，预计2025年将达到29.4亿美 元，到2034年有望增长至1 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]